Will Manufacturing Issues Hobble Abatacept?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's decision to push back the user fee date for Bristol-Myers Squibb's rheumatoid arthritis therapy Orencia (abatacept) could have a ripple effect on the launch of the product
You may also be interested in...
Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
The rheumatoid arthritis agent is expected to be available by the end of February.
Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
The rheumatoid arthritis agent is expected to be available by the end of February.
Orencia Launch Anticipated By Bristol In Early 2006
Bristol-Myers Squibb expects to gain approval for its rheumatoid arthritis therapy Orencia "soon" and plans to launch the biologic in early 2006, CEO Peter Dolan said during the company's third quarter sales and earnings call Oct. 28